









Severity of oEsophageal Anastomotic Leak in patients after oesophagectomy: the SEAL score

Sander Ubels^{1,*} , Moniek Verstegen¹ , Bastiaan Klarenbeek¹ , Stefan Bouwense², Mark van Berge Henegouwen³ , Freek Daams³, Marc J. van Det⁴, Ewen A. Griffiths^{5,6} , Jan W. Haveman⁷, Joos Heisterkamp⁸, Renol Koshy^{9,10}, Grard Nieuwenhuijzen¹¹ , Fatih Polat¹², Peter D. Siersema¹³, Pritam Singh^{14,15}, Bas Wijnhoven¹⁶, Gerjon Hannink¹⁷, Frans van Workum^{1,12} , Camiel Rosman¹ , and the TENTACLE—Esophagus Collaborative Group

¹Department of Surgery, Radboud Institute for Health Sciences, Radboud University Medical Centre, Nijmegen, the Netherlands

²Department of Surgery, Maastricht University Medical Centre+, Maastricht, the Netherlands

³Department of Surgery, Amsterdam UMC, Cancer Centre Amsterdam, University of Amsterdam, Amsterdam, the Netherlands

⁴Department of Surgery, ZGT hospital group, Almelo, the Netherlands

⁵Department of Upper Gastrointestinal Surgery, University Hospitals Birmingham NHS Foundation Trust, Queen Elizabeth Hospital Birmingham, Birmingham, UK

⁶Institute of Cancer and Genomic Sciences, College of Medical and Dental Sciences, University of Birmingham, Birmingham, UK

⁷Department of Surgery, University Medical Centre Groningen, University of Groningen, Groningen, the Netherlands

⁸Department of Surgery, Elisabeth-TweeSteden Hospital, Tilburg, the Netherlands

⁹Department of Surgery, Newcastle upon Tyne Hospital NHS Trust, Newcastle upon Tyne, UK

¹⁰Department of Surgery, University Hospitals of Coventry and Warwickshire NHS Trust, Coventry, UK

¹¹Department of Surgery, Catharina Hospital, Eindhoven, the Netherlands

¹²Department of Surgery, Canisius-Wilhelmina Hospital, Nijmegen, the Netherlands

¹³Department of Gastroenterology and Hepatology, Radboud Institute for Health Sciences, Radboud University Medical Centre, Nijmegen, The Netherlands

¹⁴Department of Surgery, Nottingham University Hospitals NHS Trust, Nottingham, UK

¹⁵Department of Surgery, Regional Oesophago-Gastric Unit, Royal Surrey County Hospital, Guildford, UK

¹⁶Department of Surgery, Erasmus University Medical Centre, Rotterdam, the Netherlands

¹⁷Department of Operating Rooms, Radboud Institute for Health Sciences, Radboud University Medical Centre, Nijmegen, The Netherlands

*Correspondence to: Sander Ubels, Department of Surgery, Radboud University Medical Centre, PO Box 9101, 6500 HB, Nijmegen, the Netherlands (e-mail: sander.ubels@radboudumc.nl)

Members of the TENTACLE—Esophagus Collaborative Group are collaborators of this study and are listed under the heading Collaborators.

1st joint congress of the European Society for Diseases of the Esophagus (ESDE) and International Gastric Cancer Association (IGCA), Milan, Italy; published in abstract form as *Dis Esophagus* 2022;**35** (Suppl 1):doac015.124. doi:10.1093/dote/doac015.124

Abstract

Background: Anastomotic leak (AL) is a common but severe complication after oesophagectomy. It is unknown how to determine the severity of AL objectively at diagnosis. Determining leak severity may guide treatment decisions and improve future research. This study aimed to identify leak-related prognostic factors for mortality, and to develop a Severity of oEsophageal Anastomotic Leak (SEAL) score.

Methods: This international, retrospective cohort study in 71 centres worldwide included patients with AL after oesophagectomy between 2011 and 2019. The primary endpoint was 90-day mortality. Leak-related prognostic factors were identified after adjusting for confounders and were included in multivariable logistic regression to develop the SEAL score. Four classes of leak severity (mild, moderate, severe, and critical) were defined based on the risk of 90-day mortality, and the score was validated internally.

Results: Some 1509 patients with AL were included and the 90-day mortality rate was 11.7 per cent. Twelve leak-related prognostic factors were included in the SEAL score. The score showed good calibration and discrimination (c-index 0.77, 95 per cent c.i. 0.73 to 0.81). Higher classes of leak severity graded by the SEAL score were associated with a significant increase in duration of ICU stay, healing time, Comprehensive Complication Index score, and Esophagectomy Complications Consensus Group classification.

Conclusion: The SEAL score grades leak severity into four classes by combining 12 leak-related predictors and can be used to assess severity of AL after oesophagectomy.

Introduction

Anastomotic leak (AL) is a major complication after oesophagectomy, and leak rates of between 10 and 20 per cent have been reported^{1–3}. Annually, an estimated 20 000 patients worldwide may develop AL after oesophagectomy^{1,4–6}. AL is associated with increased postoperative morbidity, high

postoperative mortality rates, prolonged hospital admission, and increased hospital costs^{1,7–10}. In addition, it has been shown to decrease long-term quality of life and oncological survival^{11–13}.

The clinical presentation of patients with AL is diverse and its impact ranges widely. Patients may or may not present with signs of systemic infection, contaminated fluid collections,

Received: March 25, 2021. Revised: May 02, 2022. Accepted: May 31, 2022

© The Author(s) 2022. Published by Oxford University Press on behalf of BJS Society Ltd.

This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (<https://creativecommons.org/licenses/by-nc/4.0/>), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited.

For commercial re-use, please contact journals.permissions@oup.com

and/or conduit necrosis. Currently, it is not known how to determine the severity of AL at diagnosis, but a better understanding of its severity may guide treatment strategies. Furthermore, a tool to assess leak severity could improve the comparability of future research and may be used to correct for leak severity. Therefore, a tool to assess the severity of AL at diagnosis is needed.

AL is currently classified according to the definition of the Esophagectomy Complications Consensus Group (ECCG)¹⁴. Aimed at improving benchmarking and consistent reporting of research outcomes, this classification is based on the invasiveness of the leak treatment (conservative, radiological or endoscopic intervention, and surgical intervention). However, this system does not reflect the severity of AL in terms of outcome. In addition, as the score is determined in hindsight by the treatment performed, this classification cannot guide treatment decisions in clinical practice. The ultimate measure of leak severity is the risk of death. AL severity should be determined by leak-related parameters that are available at diagnosis to enable adequate decision-making based on AL severity. However, only small and heterogeneous cohort studies^{1,9,15–19} have investigated which leak-related factors are associated with leak severity, and no comprehensive severity score has been developed.

The aims of this study were to identify leak-related prognostic factors for 90-day mortality in patients with AL after oesophagectomy with gastric tube reconstruction for cancer, and to develop a Severity of oEsophageal Anastomotic Leak (SEAL) score to classify the severity of AL at diagnosis in these patients.

Methods

Study design

TENTACLE—Esophagus (Treatment of Anastomotic Leakage after Esophagectomy) is an international multicentre retrospective cohort study. Centres performing oesophageal cancer surgery were invited to participate and the study was performed in collaboration with the Dutch Upper Gastrointestinal Cancer Audit, Oesophago-Gastric Anastomosis Audit, and European Minimally Invasive Esophagectomy Think Tank initiative. Participation was allowed irrespective of geography and patient volume. Seventy-one centres from 20 different countries participated in this study (Table S1).

The study protocol was approved by the institutional review board of Radboud University Medical Centre, and by local ethics committees of participating centres if additional approval was needed. The need for individual informed consent was waived owing to the retrospective study design and anonymous data collection. This study was performed according to TRIPOD guidelines²⁰. The TENTACLE—Esophagus study is registered in the Clinical Trials registry (NCT03829098) and the full study protocol is accessible at <https://www.tentaclestudy.com>.

Population

Adults who developed AL after oesophagectomy with gastric tube reconstruction for resectable cancer of the oesophagus or gastro-oesophageal junction (cT1–4a N0–3 M0) between January 2011 and June 2019 were included consecutively. AL was defined as a ‘full-thickness gastrointestinal defect involving oesophagus, anastomosis, staple line or conduit, irrespective of presentation or method of identification’¹⁴. Patients who were diagnosed with AL after death or who underwent an emergency

oesophagectomy or oesophagectomy for benign disease were excluded.

Data collection, verification, and quality validation

Data were collected by local investigators at each participating centre and recorded in an online database (www.castoredc.com). Data were pseudoanonymized and traceable patient data were stored locally.

To ensure robustness of data and to minimize the risk of incomplete patient inclusion, data verification and data quality validation were undertaken (Appendix S1). For data verification, an algorithm was developed to screen all data fields for inconsistent entries, typographical errors, and missing values. Data quality validation was performed by independent local validators to assess case ascertainment and data accuracy. Case ascertainment was assessed by comparing a centre’s number of included patients with the expected number of leaks based on the centre’s annual resection rate and expected minimum leak rate of 5 per cent. Data accuracy was assessed by retrieving 15 key parameters from medical records and comparing these with study data.

Outcome measures

The primary outcome was 90-day mortality, defined as death from any cause within 90 days after oesophagectomy. Mortality was used as a proxy for leak severity, and 90-day mortality was chosen because it reflects most complication-related deaths without including deaths unrelated to AL (such as early recurrence)^{21,22}. Secondary outcomes were used to assess the clinical relevance of the SEAL score and included in-hospital, 30-day, and 180-day mortality, duration of ICU and hospital stay, time to leak healing (confirmed by imaging or clinically if patients were put on (at least) a non-clear liquid diet), Comprehensive Complication Index (CCI) score, and ECCG classification. The CCI represents the severity of all complications, ranging from 0 (no complications) to 100 (death)²³. The ECCG classification consists of three leak types: type I, AL requiring medical, dietary or no therapy; type II, AL requiring reintervention but not surgical reintervention; and type III, requiring surgical therapy¹⁴.

Prognostic factors and predictors

Potential leak-related prognostic factors for 90-day mortality and predictors for the SEAL score were selected based on the literature and expert opinion. Although preoperative parameters (such as age or co-morbidity) may affect outcomes, these factors do not reflect the severity of the leak itself, and so were not included as predictors in the SEAL score. Grading of AL severity may be considered analogously to grading of tumours; although parameters such as age or co-morbidity affect outcomes and are often taken into account when making treatment decisions, the tumour itself is graded by its size and extent of dissemination²⁴. Similarly, in the SEAL score, the leak itself is graded by leak-related parameters at diagnosis and preoperative parameters were not included in this score (Table 1).

Statistical analysis

Multiple imputation using chained equations was used to reduce bias in results owing to missing data. Additional information on (handling of) missing data is presented in Appendix S2 and Table S2²⁵.

Table 1 Potential leak-related prognostic factors and SEAL score predictors

Leak-related parameters
Nasogastric tube at diagnosis
Anastomotic reinforcement
C-reactive protein
SEAL score predictors
POD of diagnosis*
Level of care at diagnosis*
Diet at diagnosis*
Leucocyte count*
Resection type*
qSOFA score*
Haemodynamic failure*
Respiratory failure*
Renal failure*
Intrathoracic fluid collections*
Defect circumference*
Overall condition conduit*

*Leak-related parameters identified as prognostic factors after adjusting for confounders were included as predictors of the Severity of oEsophageal Anastomotic leak (SEAL) score to determine leak severity. POD, postoperative day; qSOFA, quick Sequential Organ Failure Assessment.

Prognostic factors for 90-day mortality were identified by assessing the effect of individual parameters on 90-day mortality. Crude and adjusted ORs and 95 per cent confidence intervals were estimated using univariable and multivariable logistic regression analyses. Confounding variables used for adjustment of each potential prognostic factor were selected using a directed acyclic graph (DAG) ([Appendix S3 and Fig. S1](#))²⁶.

The SEAL score was developed using multivariable logistic regression to determine the risk of 90-day mortality ([Appendix S4](#)). Leak-related parameters identified as prognostic factors after adjustment for confounders were included as predictors for the SEAL score. Predictors for the SEAL score were not selected using backwards selection as described in the online protocol, but were selected using the DAG approach as inclusion of causal predictors may benefit model performance^{27,28}. The model was validated internally using bootstrapping techniques (500 replicates). Model coefficients were adjusted for the shrinkage factor found during bootstrapping. After internal validation, the model performance was re-evaluated. Model performance was assessed in terms of discrimination expressed as concordance index (c-index) and calibration using a calibration plot²⁹. A sensitivity analysis was undertaken, assessing model performance in subgroups based on geographical location.

The SEAL score was divided into four classes of AL severity: mild, moderate, severe, and critical. Class cut-off values were predefined by the study group based on clinical judgement of AL severity in relation to the risk of 90-day mortality: mild, less than 5 per cent; moderate, ≥ 5 – <15 per cent; severe, ≥ 15 – <25 per cent; and critical, at least 25 per cent predicted risk of 90-day mortality. Secondary outcomes were compared between different classes of leak severity using the χ^2 test for ordinal outcomes and one-way ANOVA for continuous outcomes. $P < 0.050$ was considered statistically significant. All statistical analyses were performed in each imputed data set and pooled subsequently using R version 3.6.2 with packages *rms* and *mi* (R Foundation for Statistical Computing, Vienna, Austria)³⁰.

Results

Preoperative characteristics

A total of 1514 patients with AL were included in the database. Five patients were excluded owing to locally advanced disease

Table 2 Preoperative patient characteristics

	Overall (n = 1509)
Age (years), median (i.q.r.)	66 (59–71)
Sex	
F	287 (19.0)
M	1222 (81.0)
BMI (kg/m ²), median (i.q.r.)	26 (23–29)
Missing	123 (8.2)
Comorbidity	
ASA 1	143 (9.5)
ASA 2	845 (56.0)
ASA 3	469 (31.1)
ASA 4	19 (1.3)
Missing	33 (2.2)
Performance status	
ECOG 0	666 (44.1)
ECOG 1	425 (28.2)
ECOG 2	88 (5.8)
ECOG 3	8 (0.5)
ECOG 4	3 (0.2)
Missing	319 (21.1)
Tumour type	
Adenocarcinoma	1088 (72.1)
SCC	377 (25.0)
Other	38 (2.5)
Missing	6 (0.4)
Tumour location	
Cervical	19 (1.3)
Upper thoracic	54 (3.6)
Mid thoracic	229 (15.2)
Lower thoracic	779 (51.6)
GOJ	418 (27.7)
Missing	10 (0.7)
Clinical T-stage	
cTis	17 (1.1)
cT1	169 (11.2)
cT2	298 (19.7)
cT3	926 (61.4)
cT4a	48 (3.2)
cTx	51 (3.4)
Clinical N-stage	
cN0	595 (39.4)
cN1	522 (34.6)
cN2	215 (14.2)
cN3	51 (3.4)
cN+	87 (5.8)
cNx	39 (2.6)
Neoadjuvant treatment	
None	301 (19.9)
Chemoradiotherapy	352 (22.3)
Chemotherapy	842 (55.8)
Radiotherapy	6 (0.4)
Missing	8 (0.5)

Values are n (%) unless otherwise indicated. BMI, body mass index; ASA, American Society of Anesthesiologists; ECOG, Eastern Cooperative Oncology Group; SCC, squamous cell carcinoma; GOJ, gastro-oesophageal junction.

(cT4b) (3 patients), oesophagojejunal reconstruction (1), and post-mortem diagnosis of AL (1). Preoperative characteristics of 1509 patients included in the analysis are shown in [Table 2](#).

Data quality validation

Of the 71 participating centres, 9 (13 per cent) included a smaller sample than expected. The patient screening procedures at these centres were reviewed and were found appropriate in 8 centres. One centre, which included 3 patients, rescreened their records and included 3 additional patients. Of 1514 records, 182 (12.0 per cent) were validated for data accuracy assessment and overall data accuracy was 96.5 per cent ([Appendix S1](#)).

Table 3 Leak-related parameters at diagnosis of anastomotic leak

Leak parameter	Value	Leak parameter	Value
POD of diagnosis, median (i.q.r.)	8 (5–11)	Leucocyte count ($\times 10^9/l$), median (i.q.r.)	12.3 (9.4, 16.1)
Missing	140 (9.3)	Missing	87 (5.8)
Diagnostic modality		CRP (mg/l), median (i.q.r.)	190 (114, 278)
Endoscopy	182 (12.1)	Missing	175 (11.6)
Oesophagography	205 (13.6)	Haemodynamic failure	
CT	743 (49.2)	No	1226 (81.2)
Fluids from drain/wound	260 (17.2)	Yes	137 (9.1)
Reoperation	23 (1.5)	Missing	146 (9.7)
Other	54 (3.6)	Respiratory failure	
None	14 (0.9)	No	1135 (75.2)
Missing	28 (1.9)	Yes	255 (16.9)
Resection type		Missing	119 (7.9)
TTO-CA	407 (27.0)	Renal failure	
TTO-IA	849 (56.3)	No	1329 (88.1)
THO-CA	241 (16.0)	Yes	55 (3.6)
Missing	12 (0.8)	Missing	125 (8.3)
Resection approach		qSOFA score	
Open	528 (35.0)	0	711 (47.1)
Hybrid, thoracoscopic	73 (4.8)	1	234 (15.5)
Hybrid, laparoscopic	167 (11.1)	2	97 (6.4)
TMIO	664 (44.0)	3	51 (3.4)
RAMIO	69 (4.6)	Missing	416 (27.6)
Missing	8 (0.5)	Intrathoracic fluid collections	
Omental wrap		None	519 (34.4)
No	986 (65.3)	Drained	139 (9.2)
Yes	380 (25.2)	Undrained	686 (45.5)
Missing	143 (9.5)	Missing	165 (10.9)
Level of care at diagnosis		Defect circumference (%)	
Surgical ward	862 (57.1)	<25	570 (37.8)
ICU, MC, HC, PACU	543 (36.0)	≥ 25	193 (12.8)
ED, other	61 (4.0)	Not available	745 (49.4)
Missing	43 (2.8)	Missing	1 (0.0)
Diet at diagnosis		Overall conduit condition	
No restriction	168 (11.1)	Well perfused	1084 (71.8)
Liquids	371 (24.6)	Ischaemic/necrotic	148 (9.8)
Water	158 (10.5)	Not available	276 (18.4)
Nil by mouth	612 (40.6)	Missing	1 (0.0)
Missing	200 (13.3)		

Values are *n* (%) unless otherwise indicated. POD, postoperative day; CT, computed tomography; TTO, transthoracic oesophagectomy; CA, cervical anastomosis; IA, intrathoracic anastomosis; THO, transhiatal oesophagectomy; TMIO, total minimally invasive oesophagectomy; RAMIO, robot-assisted minimally invasive oesophagectomy; ICU, intensive care unit; MC, medium care; HC, high care; PACU, postanesthesia care unit; ED, emergency department; CRP, C-reactive protein; qSOFA, quick Sequential Organ Failure Assessment.

Leak-related parameters at diagnosis of anastomotic leak

The median postoperative day (POD) of diagnosis (defined as confirmation of AL by clinical, imaging or other assessment) was day 8 (i.q.r. 5–11) days after oesophagectomy. Most patients (56.3 per cent) had undergone transthoracic oesophagectomy with intrathoracic anastomosis; 27.0 per cent had undergone transthoracic oesophagectomy with cervical anastomosis, and 16.0 per cent transhiatal oesophagectomy. At diagnosis of AL, 57.1 per cent of patients were on the surgical ward and 36.0 per cent in a high-care department. AL was most often diagnosed by CT, drain fluids, oesophagography, and endoscopy (49.2, 17.2, 13.6, and 12.1 per cent respectively). Some 54.7 per cent of patients had intrathoracic fluid collections (i.e. drained or undrained, mediastinal or pleural), 16.3 per cent had cervical fluid collections, and 20.6 per cent had no fluid collections. A defect circumference of 25 per cent or more was observed in 12.8 per cent of patients. Overall conduit ischaemia/necrosis was found in 9.8 per cent (Table 3).

Outcomes

The 90-day mortality rate was 11.7 per cent (176 deaths), and 30-day, 180-day and in-hospital mortality rates were 5.2, 15.9, and 10.7 per cent respectively. The median duration of hospital

stay was 30 (i.q.r. 20–49) days and of ICU stay was 6 (2–15) days. The anastomotic defect healed in 1270 patients (84.2 per cent) and the median time to healing was 26 (i.q.r. 13–46) days. The median CCI score was 44 (i.q.r. 31–64). Of all patients, 27.3 per cent had an ECG type I leak, 36.8 per cent a type II leak, and 36.0 per cent a type III leak.

Prognostic factors for mortality

Crude and adjusted ORs for possible prognostic factors for 90-day mortality are presented in Table S3. The following leak-related parameters at diagnosis of AL were identified as prognostic factors: early or late diagnosis of AL (before POD 5 and after POD 11), organ failure (respiratory failure, haemodynamic failure, renal failure or raised quick Sequential Organ Failure Assessment (qSOFA) score), admission to a high-care unit, leucopenia and leucocytosis, presence of intrathoracic fluid collections (drained and/or undrained), defect circumference at least 25 per cent, and overall conduit ischaemia/necrosis. AL after transhiatal oesophagectomy and a diet consisting of water only (*versus* nil by mouth, liquid or unrestricted diet) at diagnosis were associated with reduced 90-day mortality. Anastomotic reinforcement (omental wrap/pleural flap), nasogastric tube at diagnosis, and C-reactive protein (CRP) levels at diagnosis were not identified as leak-related prognostic factors.

SEAL score development and internal validation

The SEAL score was developed by including all 12 identified prognostic leak-related parameters in a multivariable logistic regression model (Table 4). After internal validation, the c-index for the SEAL score was 0.77 (95 per cent c.i. 0.73 to 0.81) and the SEAL score showed good calibration (Fig. 1).

Outcomes for patients in different AL severity classes according to the SEAL score are summarized in Table 5, including an example of a patient in each class. The majority of patients (51.2 per cent) were classified as having a moderate AL; 25.4 per cent had mild, 13.4 per cent severe, and 10.1 per cent had critical leak. There was good alignment between the observed and predicted mortality rate within each leak severity class. Patients with greater leak severity had a statistically significantly longer duration of hospital (and ICU) stay, longer time to leak healing, higher mortality rate (in-hospital, 30-day, 90-day, and 180-day mortality), and higher CCI score. Furthermore, the percentage of ECCG type I leaks declined, whereas the percentage of ECCG type III leaks increased. Model performance was good among 1401 patients treated in European centres, but could not be assessed accurately in 108 patients treated in non-European centres owing to the limited number of patients (Fig. S2).

The internally validated SEAL score was incorporated into an online application, which enables determination of leak severity and is available at <https://www.tentaclestudy.com/seal-score>.

Discussion

The SEAL score classifies patients with AL into four classes of leak severity according to the predicted risk of 90-day mortality. The score combines 12 leak-related prognostic factors at diagnosis, and showed good performance after internal validation. A more

severe leak according to the SEAL score was associated with a longer duration of hospital and ICU stay, longer healing time, higher CCI score, and higher ECCG grade, indicating that this score is relevant beyond 90-day mortality. This unique cohort enabled identification of prognostic factors, and development and internal validation of the SEAL score.

Some limitations should, however, be discussed. There is a risk of bias owing to patient selection, but the patients were consecutive and the data validated. Patients with subclinical AL may be under-represented as they may not have been identified during screening for eligible patients. Such patients may not require admission or treatment; this is not the targeted population for the SEAL score, and omission of these patients therefore has few consequences. A recent prospective international audit¹, which included all patients undergoing oesophagectomy, found an AL rate of 14.2 per cent, with an AL mortality rate similar to that in the present study, indicating comparability of cohorts.

Appropriate measures were taken to ensure data quality; meticulous data verification was performed to ensure uniform data collection and data quality validation showed good data accuracy, similar to other surgical studies^{31–33}. Multiple imputation was used to increase precision and avoid bias during the analysis²⁵. Still, the high rate of unavailable data on defect circumference reflects current diagnostic strategies and limited reporting of endoscopic findings. The prognostic impact of defect circumference and conduit condition underscores the importance of endoscopy as a diagnostic assessment, and detailed reporting of imaging assessments may further improve the data quality of future studies. Even though the SEAL score was developed in a large international cohort and was validated internally, it is unknown whether the findings can be

Table 4 The SEAL score after internal validation

Predictor	Odds ratio
POD of diagnosis*	1.43 (0.89, 2.29)
Level of care at diagnosis	
Surgical ward	1.00 (reference)
ICU, MC, HC, PACU	1.83 (1.19, 2.82)
Other	1.31 (0.52, 3.29)
Diet at diagnosis	
Unrestricted	1.00 (reference)
Liquids	0.87 (0.46, 1.65)
Water	0.45 (0.17, 1.21)
Nil by mouth	1.02 (0.54, 1.90)
qSOFA score (per point)	1.21 (0.88, 1.66)
Respiratory failure	1.53 (0.90, 2.60)
Haemodynamic failure	1.14 (0.62, 2.13)
Renal failure	2.48 (1.30, 4.73)
Leucocyte count*	0.92 (0.70, 1.20)
Resection type	
TTO-CA	1.00 (reference)
TTO-IA	0.69 (0.46, 1.04)
THO-CA	0.68 (0.37, 1.26)
Defect circumference $\geq 25\%$	1.66 (1.08, 2.57)
Overall conduit ischaemia/necrosis	1.20 (0.73, 1.98)
Intrathoracic collections	
None	1.00 (reference)
Drained	1.48 (0.78, 2.82)
Undrained	1.52 (0.98, 2.37)

Values in parentheses are 95 per cent confidence intervals. *Interquartile OR, i.q.r.: postoperative day (POD) of diagnosis 5–11 days, leucocyte count $9.3\text{--}16.1 \times 10^9/\text{l}$. SEAL, Severity of oEsophageal Anastomotic Leak; ICU, intensive care unit; MC, medium care; HC, high care; PACU, postanesthesia care unit; qSOFA, quick Sequential Organ Failure Assessment; TTO, transthoracic oesophagectomy; CA, cervical anastomosis; IA, intrathoracic anastomosis; THO, transhiatal oesophagectomy.




Fig. 1 Calibration plot of the SEAL score

The calibration slope was 1.12 (95 per cent c.i. 0.93 to 1.31) and resembles the strength of predictors. The calibration intercept was 0.00 (95 per cent c.i. –0.17 to 0.17), and resembles the ‘calibration in the large’ indicating whether the model systematically overpredicts or underpredicts. Discrimination: c-index 0.77 (95 per cent c.i. 0.73 to 0.81). The shaded area displays the 95 per cent confidence interval of the flexible calibration curve. The triangles plotted in the calibration curve represent observed proportion versus predicted probabilities for decile predictions, with error bars indicating 95 per cent confidence interval for a specific decile. The broom plot at the bottom shows the distribution of predicted probabilities for 90-day mortality in patients who did (1) or did not (0) die within 90 days. SEAL, Severity of oEsophageal Anastomotic Leak.

Table 5 Pooled outcomes according to the SEAL score

	SEAL score (predicted risk of 90-day mortality)			
	Mild (<5%)	Moderate (≥5-<15%)	Severe (≥15-<25%)	Critical (≥25%)
Example	Patient diagnosed on surgical ward, on a water diet and with a small defect and viable conduit. No organ failure or intrathoracic fluid collections	Patient presenting with intrathoracic collections or a large defect, with leucocytosis and tachypnoea or hypotension	Patient diagnosed on POD 3 in ICU with single organ failure, together with intrathoracic fluid collections or a large anastomotic defect	Complex presentation, patient with multiple organ failure and combination of intrathoracic fluid collections, large defect and/or conduit necrosis
% of patients, range*	25.4 (21–30)	51.2 (47–56)	13.4 (12–15)	10.1 (9–11)
Predicted mortality risk (%), range*†	3.6 (3–4)	8.8 (8–9)	19.2 (19–20)	36.6 (36–38)
90-day mortality (%), range*†	3.0 (2–4)	8.0 (7–9)	23.5 (18–27)	36.6 (33–40)
30-day mortality (%), range*†	0.5 (0–1)	3.3 (3–4)	8.3 (6–11)	22.1 (20–24)
180-day mortality (%), range*†	5.8 (4–7)	12.3 (11–13)	28.5 (23–33)	43.6 (39–47)
In-hospital mortality (%), range*†	1.8 (1–3)	7.2 (6–8)	21.3 (16–25)	37.6 (35–41)
Duration of hospital stay (mean, days), range*†	27 (26–29)	39 (38–41)	52 (48–57)	50 (48–53)
Duration of ICU stay (mean, days), range*†	5 (4–5)	11 (10–12)	22 (19–24)	28 (27–30)
Leak healing time (mean, days), range*†	30 (28–32)	35 (33–36)	41 (36–48)	43 (39–51)
CCI score (mean), range*†	34 (33–35)	46 (45–47)	64 (62–66)	77 (75–79)
ECCG classification (%), range*†				
Type I	42.8 (40–48)	28.1 (25–31)	12.5 (9–16)	3.5 (1–7)
Type II	36.8 (34–40)	38.7 (36–42)	33.9 (28–38)	30.4 (25–34)
Type III	20.5 (17–23)	33.2 (31–36)	53.6 (50–60)	66.1 (62–72)

*Range across imputations. SEAL, Severity of oEsophageal Anastomotic Leak; ICU, intensive care unit; POD, postoperative day; CCI, Comprehensive Complication index; ECCG, Esophagectomy Complications Consensus Group. †P < 0.010 (χ² test for ordinal outcomes, 1-way ANOVA for continuous outcomes).

generalized²⁹. Independent external validation of the SEAL score should be undertaken as model performance could not be assessed accurately in centres outside Europe. However, external validation requires an additional large and detailed data set, which is not currently available.

The study has identified an array of leak-related prognostic factors in patients with AL, highlighting the complex and multifactorial character of AL severity. The present findings have confirmed previous suggestions that defect circumference, intrathoracic fluid collections, and conduit condition have a high prognostic impact^{1,15,17–19}. Patients with a diet consisting of water only at diagnosis were found to have better outcomes. As drinking water may help limit contamination, these patients could be less prone to developing sepsis. Interestingly, although CRP may have an important role in diagnosing AL^{34–36}, the present findings indicated that CRP levels do not reflect AL severity at diagnosis. Contrary to popular belief, anastomotic reinforcement (omental wrap) was not found to reduce the severity of AL^{37–40}. Transhiatal oesophagectomy was identified as a favourable prognostic factor, and the risk of developing intrathoracic manifestations may indeed be lower as no transthoracic resection is performed^{18,41,42}. However, after transthoracic oesophagectomy no difference was found regarding outcomes of cervical and intrathoracic AL, supporting the recent ‘chute hypothesis’, proposing that thoracic dissection may increase the risk of intrathoracic manifestations in cervical AL^{19,42,43}.

The SEAL score adopts a novel approach to determining AL severity by combining leak-related prognostic factors at diagnosis of AL. A higher SEAL score was associated with higher ECCG leak type, and the SEAL score expresses explicitly at diagnosis what the ECCG classification indicates implicitly once treatment has been completed¹⁴. The applicability of the ECCG classification is limited in clinical practice, whereas the SEAL

score may be used to determine the severity of AL for individual patients. Moreover, use of the SEAL score may unify understanding of the impact of AL on patients, and surgeons, gastroenterologists and other physicians may monitor patients with severe or critical AL more closely. In the future, the SEAL score may guide treatment decisions, but its role is yet to be established. For example, patients with a higher SEAL score may benefit from more aggressive (surgical) treatment. For research purposes, the ECCG classification and the SEAL score may be complementary; the ECCG classification may be used to standardize reporting of AL treatments, and the SEAL score to report leak severity. Moreover, previous studies^{1,44} were unable to assess the efficacy of AL treatments owing to confounding bias, whereas the SEAL score can be used to adjust for leak severity and may consequently reduce bias.

Development of the SEAL score is the first step towards finding evidence for the optimal treatment of AL. Future analyses of TENTACLE—Esophagus will investigate the efficacy of leak treatment taking into account AL severity; assess the association between practice variation and outcomes; and aim to develop a prediction model incorporating the SEAL score and preoperative factors to accurately predict mortality risk based on patient characteristics and leak severity.

In conclusion, the SEAL score combines leak-related parameters at diagnosis and grades leak severity into four classes based on individual predictions of 90-day mortality; the score reflects morbidity in terms of duration of hospital (and ICU) stay, healing time, CCI score, and ECCG leak type. In clinical practice, the score is instrumental in determining the severity of AL at diagnosis and may guide clinical decision-making in the future. In research, the SEAL score may be used to report and adjust for the severity of AL after oesophagectomy.

Collaborators

TENTACLE—Esophagus Collaborative Group: E. Matthée, C. A. M. Sloomans, G. Ultee, J. Schouten (Radboud university medical centre, Nijmegen, The Netherlands); S. S. Gisbertz, W. J. Eshuis, M. C. Kalff, M. L. Feenstra (Amsterdam UMC, University of Amsterdam, Cancer Centre Amsterdam, Amsterdam, The Netherlands); D. L. van der Peet, W. T. Stam (Amsterdam UMC, location VUmc, Amsterdam, The Netherlands); B. van Etten, F. Poelmann, N. Vuurberg, J. W. van den Berg (University Medical Centre Groningen, University of Groningen, Groningen, The Netherlands); I. S. Martijnse, R. M. Matthijsen (Elisabeth-Tweesteden Ziekenhuis, Tilburg, The Netherlands); M. Luyer, W. Curvers, T. Nieuwenhuijzen (Catharina Ziekenhuis Eindhoven, Eindhoven, The Netherlands); A. k. E. Taselaar (Erasmus medical centre, Rotterdam, The Netherlands); E. A. Kouwenhoven, M. Lubbers (Ziekenhuisgroep Twente, Almelo, The Netherlands); M. Sosef, F. Lecot, T. C. M. Geraedts (Zuyderland Medisch Centrum, Heerlen, The Netherlands); S. van Esser, J. W. T. Dekker (Reinier de Graaf Gasthuis, Delft, The Netherlands); F. van den Wildenberg (Canisius-Wilhelmina Ziekenhuis, Nijmegen, The Netherlands); W. Kelder, M. Lubbers, P. C. Baas, J. W. A. de Haas (Martini Ziekenhuis, Groningen, The Netherlands); H. H. Hartgrink, R. R. Bahadoer (Leiden University Medical Centre, Leiden, The Netherlands); J. W. van Sandick, K. J. Hartemink, X. Veenhof (Netherlands Cancer Institute - Antoni van Leeuwenhoek, Amsterdam, The Netherlands); H. Stockmann, B. Gorgec, P. Weeder (Spaarne Gasthuis, Haarlem, The Netherlands); M. J. Wiezer, C. M. S. Genders (St. Antonius Ziekenhuis, Nieuwegein, The Netherlands); E. Belt, B. Blomberg (Albert Schweitzer, Dordrecht, The Netherlands); P. van Duijvendijk, L. Claassen, D. Reetz (Gelre, Apeldoorn, The Netherlands); P. Steenvoorde, W. Mastboom, H. J. Klein Ganseij (Medisch Spectrum Twente, Enschede, The Netherlands); A. D. van Dalsen, A. Joldersma, M. Zwakman (Isala, Zwolle, The Netherlands); R. P. R. Groenendijk, M. Montazeri (IJsselland Ziekenhuis, Cappelle aan de IJssel, The Netherlands); St. Mercer, B. Knight, G. van Boxel (Portsmouth Hospital University Trust, Portsmouth, United Kingdom); R. J. McGregor, R. J. E. Skipworth, C. Frattini, A. Bradley (University of Edinburgh, Royal Infirmary of Edinburgh, Edinburgh, United Kingdom); M. Nilsson, M. Hayami, B. Huang (Karolinska University Hospital, Stockholm, Sweden); J. Bundred, R. Evans (Queen Elizabeth Hospital, Birmingham, United Kingdom); P. P. Grimmering, P. C. van der Sluis, U. Eren (University Medical Centre Mainz, Mainz, Germany); J. Saunders, E. Theophilidou, Z. Khanzada (Nottingham University Hospitals NHS Trust, Nottingham, United Kingdom); J. A. Elliott, J. Ponten, S. King, J. V. Reynolds (Trinity St. James's Cancer Institute, Dublin, Ireland); B. Sgromo, K. Akbari, S. Shalaby (Churchill Hospital, Oxford University Hospitals, Oxford, United Kingdom); C. A. Gutschow, H. Schmidt, D. Vetter (University Hospital Zurich, Zurich, Switzerland); K. Moorthy, M. A. H. Ibrahim, G. Christodoulidis (Imperial, London, United Kingdom); J. V. Räsänen, J. Kauppi, H. Söderström (Helsinki University Hospital, Helsinki University, Helsinki, Finland); D. K. Manatakis, D. P. Korkolis, D. Balalis, A. Rompu (Saint Savvas Cancer Hospital, Athens, Greece); B. Alkhaffaf, M. Alasmar, M. Arebi (Salford Royal NHS Foundation Trust, Division of Cancer Sciences, University of Manchester, Manchester, United Kingdom); G. Piessen, F. Nuytens, S. Degisors (University Lille, Claude Huriez University Hospital, CHU de Lille, Lille, France); A. Ahmed, A. Boddy, S. Gandhi, O. Fashina (University of Leicester, Leicester, United Kingdom);

E. Van Daele, P. Pattyn (Ghent University Hospital, Ghent, Belgium); W. B. Robb, M. Arumugasamy, M. Al Azzawi, J. Whooley (Beaumont Hospital, Dublin, Ireland); E. Colak, E. Aybar, A. C. Sari, M. S. Uyanik, A. B. Ciftci (Samsun Training and Research Hospital, Samsun, Turkey); R. Sayyed, B. Ayub, G. Murtaza, A. Saeed, P. Ramesh (Patel Hospital, Karachi, Pakistan); A. Charalabopoulos, T. Liakakos, D. Schizas, E. Baili, A. Kapelouzou (Laiko General Hospital, Athens, Greece); M. Valmasoni, E. S. Pierobon, G. Capovilla, S. Merigliano (University Hospital of Padova, Padova, Italy); C. Silviu, B. Rodica, A. Florin, R. Cristian Gelu, H. Petre (Sf. Maria Hospital, Bucharest, Romania); R. Guevara Castro, A. F. Salcedo (Clinica Universitaria Colombia, Bogota, Colombia); I. Negoii, V. M. Negoita, C. Ciubotaru, B. Stoica, S. Hostiuc (Carol Davila University of Medicine and Pharmacy Bucharest, Emergency Hospital of Bucharest, Bucharest, Romania); N. Colucci, S. P. Mönig, C. H. Wassmer, J. Meyer (Geneva University Hospitals, Geneva, Switzerland); F. R. Takeda, R. A. Aissar Sallum, U. Ribeiro, I. Ceconello (University of Sao Paulo, Sao Paulo, Brazil); E. Toledo, M. S. Trugeda, M. J. Fernández, C. Gil, S. Castanedo (Valdecilla Hospital, Santander, Spain); A. Isik, E. Kumaz (Erzincan Binali Yildirim University, Erzincan, Turkey); J. F. Videira, M. Peyroteo, R. Canotilho (Instituto Português de Oncologica, Porto, Portugal); J. Weindelmayer, S. Giacomuzzi, C. A. De Pasqual (Verona University Hospital, Verona, Italy); M. Bruna, F. Mingol, J. Vaque, C. Pérez (La Fe Hospital, Valencia, Spain); A. W. Phillips, J. Chmelo, J. Brown, L. E. Han (Royal Victoria Infirmary, Newcastle upon Tyne, United Kingdom); J. A. Gossage, A. R. Davies, C. R. Baker, M. Kelly, M. Saad (Guy's and St Thomas' Hospitals, London, United Kingdom); D. Bernardi, L. Bonavina, E. Asti, C. Riva, R. Scaramuzza (University of Milan, Milan, Italy); M. Elhadi, H. Abdelkarem Ahmed, A. Elhadi, F. A. Elnagar, A. A. Msherghi (Tripoli University Hospital, Tripoli, Libya); V. Wills, C. Campbell, M. Perez Cerdeira, S. Whiting (John Hunter New England LHD, Newcastle, Australia); N. Merrett, A. Das, C. Apostolou, A. Lorenzo (South Western Sydney Local Health District, Sydney, Australia); F. Sousa, J. Adelino Barbosa, V. Devezas, E. Barbosa, C. Fernandes (Centro Hospitalar Universitário São João, Oporto, Portugal); G. Smith, E. Y. Li, N. Bhimani, P. Chan, K. Kotecha (Royal North Shore Hospital, Sydney, Australia); M. W. Hii, S. M. Ward, M. Johnson, M. Read, L. Chong (St Vincent's Hospital, Melbourne, Australia); M. J. Hollands, M. Allaway, A. Richardson, E. Johnston, A. Z. L. Chen (Westmead Hospital, Sydney, Australia); H. Kanhere, S. Prasad, P. McQuillan, T. Surman (Royal Adelaide Hospital, Adelaide, Australia); M. I. Trochsler, W. A. Schofield, S. K. Ahmed, J. L. Reid, M. C. Harris (The Queen Elizabeth Hospital, Adelaide, Australia); S. Gananadha, J. Farrant, N. Rodrigues, J. Fergusson (Canberra Hospital, Canberra, Australia); A. Hindmarsh, Z. Afzal, P. Safranek, V. Sujendran, S. Rooney (Addenbrooke's hospital, Cambridge, United Kingdom); C. Loureiro, S. Leturio Fernández, I. Díez del Val (University Hospital Basurto, Bilbao, Spain); S. Jaunoo, L. Kennedy, A. Hussain (Brighton & Sussex University Hospitals, Brighton, United Kingdom); D. Theodorou, T. Triantafyllou, C. Theodoropoulos, T. Palyvou (Hippocraton hospital, Athens, Greece); M. Elhadi, F. Abdullah Ben Taher, M. Ekheel, A. A. A. Msherghi (Sabratha National Cancer Institute, Sabratha, Libya).

Funding

The TENTACLE—Esophagus study received funding from Medtronic. The study was performed independently, and

Medtronic had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript.

Acknowledgements

S.U. and M.V. contributed equally as first authors; F.v.W and C.R. contributed equally as senior authors. The authors thanks all those involved in the TENTACLE—Esophagus study for their contribution to this large international study. The TENTACLE—Esophagus study was registered in the Clinical Trials registry (NCT03829098) before the start of the study. Study data are not openly available. The authors are willing to share data upon reasonable request to the corresponding authors.

Disclosure. All authors declare funding from Medtronic for the submitted work. P.S. reports grants from The Enose Company, grants and other from Motus GI, grants from Pentax, grants from Micro-Tech, and other from Boston Scientific, outside the submitted work; B.K. reports grants from Medtronic and ZonMw, outside the submitted work; M.v.B.H. reports other from Mylan, other from Alesi Surgical, other from Johnson and Johnson, other from BBraun, other from Medtronic, grants from Olympus, and grants from Stryker, outside the submitted work; all fees unrelated to submitted work, paid to institution. The authors declare no other conflict of interest.

Supplementary material

Supplementary material is available at *BJS* online.

References

- Oesophago-Gastric Anastomosis Study Group; West Midlands Research Collaborative. Rates of anastomotic complications and their management following esophagectomy: results of the Oesophago-Gastric Anastomosis Audit (OGAA). *Ann Surg* 2022;**275**:382–390
- van Workum F, Verstegen MHP, Klarenbeek BR, Bouwense SAW, van Berge Henegouwen MI, Daams F et al. Intrathoracic vs cervical anastomosis after totally or hybrid minimally invasive esophagectomy for esophageal cancer: a randomized clinical trial. *JAMA Surg* 2021;**156**:601–610
- Kuppusamy MK, Low DE; International Esodata Study Group. Evaluation of international contemporary operative outcomes and management trends associated with esophagectomy: a 4-year study of > 6000 patients using ECCG definitions and the online Esodata database. *Ann Surg* 2020;**275**:515–525
- Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *CA Cancer J Clin* 2018;**68**:394–424
- Dutch Upper Gastrointestinal Cancer Audit. *Core Figures 2015–2019 (Basis Tabel 2015–2019)*. Leiden: Dutch Institute for Cancer Auditing, 2020
- Netherlands Cancer Registry (NCR). *NCR Figures (NKR Cijfers)*. Netherlands Comprehensive Cancer Organisation (IKNL), 2019. <https://iknl.nl/nkr-cijfers> (accessed 10 December 2021)
- Biere SSAY, van Berge Henegouwen MI, Maas KW, Bonavina L, Rosman C, Garcia JR et al. Minimally invasive versus open oesophagectomy for patients with oesophageal cancer: a multicentre, open-label, randomised controlled trial. *Lancet* 2012;**379**:1887–1892
- Goense L, Meziani J, Ruurda JP, van Hillegersberg R. Impact of postoperative complications on outcomes after esophagectomy for cancer. *Br J Surg* 2018;**106**:111–119
- Turkyilmaz A, Eroglu A, Aydin Y, Tekinbas C, Muharrem Erol M, Karaoglanoglu N. The management of esophagogastric anastomotic leak after esophagectomy for esophageal carcinoma. *Dis Esophagus* 2009;**22**:119–126
- Lubbers M, Workum F, Berkelmans G, Rosman C, Luyer M, Nieuwenhuijzen G et al. Variations in treatment of an anastomotic leakage after Ivor Lewis esophagectomy. *J Clin Images Med Case Rep* 2021;**2**:1417
- Fransen LFC, Berkelmans GHK, Asti E, van Berge Henegouwen MI, Berlth F, Bonavina L et al. The effect of postoperative complications after minimally invasive esophagectomy on long-term survival: an international multicenter cohort study. *Ann Surg* 2021;**274**:e1129–e1137
- Derogar M, Orsini N, Sadr-Azodi O, Lagergren P. Influence of major postoperative complications on health-related quality of life among long-term survivors of esophageal cancer surgery. *J Clin Oncol* 2012;**30**:1615–1619
- Scarpa M, Saadeh LM, Fasolo A, Alfieri R, Cagol M, Cavallin F et al. Health-related quality of life in patients with oesophageal cancer: analysis at different steps of the treatment pathway. *J Gastrointest Surg* 2013;**17**:421–433
- Low DE, Alderson D, Ceconello I, Chang AC, Darling GE, D'Journo XB et al. International consensus on standardization of data collection for complications associated with esophagectomy: Esophagectomy Complications Consensus Group (ECCG). *Ann Surg* 2015;**262**:286–294
- Manghelli JL, Ceppa DP, Greenberg JW, Blitzer D, Hicks A, Rieger KM et al. Management of anastomotic leaks following esophagectomy: when to intervene? *J Thorac Dis* 2019;**11**:131–137
- Guo J, Chu X, Liu Y, Zhou N, Ma Y, Liang C. Choice of therapeutic strategies in intrathoracic anastomotic leak following esophagectomy. *World J Surg Oncol* 2014;**12**:402
- Alanezi K, Urschel JD. Mortality secondary to esophageal anastomotic leak. *Ann Thorac Cardiovasc Surg* 2004;**10**:71–75
- Korst RJ, Port JL, Lee PC, Altorki NK. Intrathoracic manifestations of cervical anastomotic leaks after transthoracic esophagectomy for carcinoma. *Ann Thorac Surg* 2005;**80**:1185–1190
- van Rossum PSN, Haverkamp L, Carvello M, Ruurda JP, van Hillegersberg R. Management and outcome of cervical versus intrathoracic manifestation of cervical anastomotic leakage after transthoracic esophagectomy for cancer. *Dis Esophagus* 2017;**30**:1–8
- Collins GS, Reitsma JB, Altman DG, Moons KG. Transparent reporting of a multivariable prediction model for individual prognosis or diagnosis (TRIPOD): the TRIPOD statement. *BMC Med* 2015;**13**:1
- In H, Palis BE, Merkow RP, Posner MC, Ferguson MK, Winchester DP et al. Doubling of 30-day mortality by 90 days after esophagectomy: a critical measure of outcomes for quality improvement. *Ann Surg* 2016;**263**:286–291
- Talsma AK, Lingsma HF, Steyerberg EW, Wijnhoven BP, Van Lanschot JJ. The 30-day versus in-hospital and 90-day mortality after esophagectomy as indicators for quality of care. *Ann Surg* 2014;**260**:267–273
- Slanckamenac K, Graf R, Barkun J, Puhon MA, Clavien PA. The comprehensive complication index: a novel

- continuous scale to measure surgical morbidity. *Ann Surg* 2013; **258**:1–7
24. Rice TW, Patil DT, Blackstone EH. 8th edition AJCC/UICC staging of cancers of the esophagus and esophagogastric junction: application to clinical practice. *Ann Cardiothorac Surg* 2017; **6**: 119–130
 25. Van Buuren S. *Flexible Imputation of Missing Data*. Boca Raton, FL: CRC Press, 2018
 26. Shrier I, Platt RW. Reducing bias through directed acyclic graphs. *BMC Med Res Methodol* 2008; **8**:70
 27. Thornley S. Causation and statistical prediction: perfect strangers or bedfellows? *J Biometric Biostat* 2012; **3**
 28. Heinze G, Dunkler D. Five myths about variable selection. *Transpl Int* 2017; **30**:6–10
 29. Collins GS, de Groot JA, Dutton S, Omar O, Shanyinde M, Tajar A et al. External validation of multivariable prediction models: a systematic review of methodological conduct and reporting. *BMC Med Res Methodol* 2014; **14**:40
 30. Wood AM, Royston P, White IR. The estimation and use of predictions for the assessment of model performance using large samples with multiply imputed data. *Biometric J* 2015; **57**: 614–632
 31. van der Werf LR, Busweiler LAD, van Sandick JW, van Berge Henegouwen MI, Wijnhoven BPL. Reporting national outcomes after esophagectomy and gastrectomy according to the Esophageal Complications Consensus Group (ECCG). *Ann Surg* 2020; **271**:1095–1101
 32. STARSurg Collaborative. Impact of postoperative non-steroidal anti-inflammatory drugs on adverse events after gastrointestinal surgery. *Br J Surg* 2014; **101**:1413–1423
 33. Bhangu A, Ademuyiwa AO, Aguilera ML, Alexander P, Al-Saqqa SW, Borda-Luque G et al. Surgical site infection after gastrointestinal surgery in high-income, middle-income, and low-income countries: a prospective, international, multicentre cohort study. *Lancet Infect Dis* 2018; **18**:516–525
 34. Barbaro A, Eldredge TA, Shenfine J. Diagnosing anastomotic leak post-esophagectomy: a systematic review. *Dis Esophagus* 2021; **34**:doaa076
 35. Aiolfi A, Asti E, Rausa E, Bonavina G, Bonitta G, Bonavina L. Use of C-reactive protein for the early prediction of anastomotic leak after esophagectomy: systematic review and Bayesian meta-analysis. *PLoS One* 2018; **13**:e0209272
 36. Liesenfeld LF, Sauer P, Diener MK, Hinz U, Schmidt T, Muller-Stich BP et al. Prognostic value of inflammatory markers for detecting anastomotic leakage after esophageal resection. *BMC Surg* 2020; **20**:324
 37. Sepesi B, Swisher SG, Walsh GL, Correa A, Mehran RJ, Rice D et al. Omental reinforcement of the thoracic esophagogastric anastomosis: an analysis of leak and reintervention rates in patients undergoing planned and salvage esophagectomy. *J Thorac Cardiovasc Surg* 2012; **144**:1146–1151
 38. Zhou D, Liu QX, Deng XF, Zheng H, Lu X, Dai JG et al. Anastomotic reinforcement with omentoplasty reduces anastomotic leakage for minimally invasive esophagectomy with cervical anastomosis. *Cancer Manag Res* 2018; **10**:257–263
 39. Zheng QF, Wang JJ, Ying MG, Liu SY. Omentoplasty in preventing anastomotic leakage of oesophagogastric anastomosis following radical oesophagectomy with three-field lymphadenectomy. *Eur J Cardiothorac Surg* 2013; **43**:274–278
 40. Chen X, Liu S, Chen P, He H, Wang F. Application of pleural flaps in laparoscopic–thoracoscopic esophagectomy for esophageal cancer. *J Thorac Dis* 2020; **12**:973–979
 41. van Heijl M, van Wijngaarden AKS, Lagarde SM, Busch ORC, van Lanschot JJB, van Berge Henegouwen MI. Intrathoracic manifestations of cervical anastomotic leaks after transhiatal and transthoracic oesophagectomy. *Br J Surg* 2010; **97**:726–731
 42. Verstegen MHP, Slaman AE, Klarenbeek BR, van Berge Henegouwen MI, Gisbertz SS, Rosman C et al. Outcomes of patients with anastomotic leakage after transhiatal, Mckeown or Ivor Lewis esophagectomy: a nationwide cohort study. *World J Surg* 2021; **45**:3341–3349
 43. Blewett CJ, Miller JD, Young JE, Bennett WF, Urschel JD. Anastomotic leaks after esophagectomy for esophageal cancer: a comparison of thoracic and cervical anastomoses. *Ann Thorac Cardiovasc Surg* 2001; **7**:75–78
 44. Verstegen MHP, Bouwense SAW, van Workum F, Ten Broek R, Siersema PD, Rovers M et al. Management of intrathoracic and cervical anastomotic leakage after esophagectomy for esophageal cancer: a systematic review. *World J Emerg Surg* 2019; **14**:17